Iambic Therapeutics has advanced its first pipeline candidate into the clinic, an AI-designed treatment for human epidermal growth factor receptor 2 (HER2)-driven cancers that moved from discovery to ...
Iambic Therapeutics is finding its rhythm, raising $100 million and partnering with the shovel seller of the artificial intelligence gold rush to advance a pipeline led by a pair of cancer candidates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback